High throughput DAR determination of brentuximab vedotin

Bioanalytical

High throughput DAR determination of brentuximab vedotin

27 May, 2020

Published over 6 years ago. See the latest and most current information on Bioanalytical.

Drug-to-antibody ratios (DAR) of antibody-drug-conjugates (ADCs) such as brentuximab vedotin is important for their therapeutic efficacy and pharmacokinetics. Therefore, control of DAR is a key factor for ADC quality control. Given that, it is important for QC purposes to obtain a satisfying resolution of all DARs and the resulting average ratio whilst performing the separation in the shortest time.

Brentuximab vedotin (Adcetris®) is a cysteine conjugated ADC targeting different types of lymphoma with an average DAR of 4. Typically, this 2nd generation ADC is analysed by hydrophobic interaction chromatography (HIC).

In this application note YMC’s latest hydrophobic interaction chromatography column, BioPro HIC HT, was used. A mobile phase of sodium phosphate buffer at neutral pH with decreasing gradients of the lyotropic salt ammonium sulphate was used. The rigid 2.3 μm non-porous polymer particles are pressure tolerant up to 400 bar and allow rapid analyses through increased flow rates without loss of resolution. This allows flow rates to be increased by 2.5 times with savings of about 60% in time.

Latest News

Explore Our Other Sites

Labmate Online
Metrohm launches OMNIS IC: a new benchmark in ion chromatography
Explore more Arrow
Envirotech Online
Phenol on the ground: what a COMAH prosecution shows about soil data as evidence
Explore more Arrow
Pollution Solutions Online
Pump and mixer service at paper mill set to reach 40 years
Explore more Arrow
Petro Online
Hydrogen sulphide deaths expose the gaps in gas detection during non-routine work
Explore more Arrow